Protecting infants from respiratory syncytial virus (RSV) remains a critical public health priority. Recent economic evaluations highlight the maternal vaccine’s (MV) cost-effectiveness during the early months of the RSV season, offering a strategic advantage in reducing hospitalizations and outpatient visits.
Cost-Effectiveness Analysis
The study utilized a Markov model to assess the cost-effectiveness of administering MV, nirsevimab, or opting for no intervention among infants born from October to February. Findings indicate that MV not only proves cost-saving in October through December but also maintains cost-effectiveness in January. However, it fails to be cost-effective in February. When considering the entire RSV season, MV stands out with a favorable cost per quality-adjusted life-year (QALY).
Clinical Outcomes
Clinically, MV significantly reduces the burden of RSV by averting tens of thousands of outpatient visits and thousands of hospitalizations. Nirsevimab shows superior performance compared to MV but only in the earlier months of the RSV season. The probability analysis underscores MV’s robustness as a cost-effective intervention across most of the RSV period.
– MV is cost-saving for three out of five monthly cohorts.
– Nirsevimab outperforms MV only in October and November.
– Overall, MV offers substantial reductions in healthcare utilization and mortality.
The economic evaluation underscores the strategic timing of vaccine administration. By targeting the initial months of the RSV season, healthcare systems can optimize resource allocation and enhance infant health outcomes. The superior performance of MV in key months suggests a tailored approach could maximize both economic and clinical benefits.
Implementing MV broadly across the first four months of the RSV season emerges as a viable strategy to mitigate healthcare costs and improve infant survival rates. Policymakers should consider these findings to refine vaccination schedules, ensuring that interventions are both economically and medically advantageous.
Future research should focus on understanding the transmission dynamics of RSV to further refine the cost-effectiveness models. Additionally, exploring the long-term benefits of MV on infant health could provide a more comprehensive picture of its value proposition.
Optimizing RSV prevention requires a nuanced approach that balances cost with health outcomes. The evidence supports prioritizing MV during peak months to achieve the best possible results for infants and the healthcare system alike.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
